1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33.
2. Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1–7.
3. program S. SEER cancer statistics review (CSR) 1975–2012. 2012. Available at: https://seer.cancer.gov/archive/csr/1975_2012/browse_csr.php?sectionSEL=4&pageSEL=sect_04_table.13.html.
4. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/dcpc/about/CDC 2022.
5. Schmid P CJ, Dent R, Pusztai L, McArthur H, Kummel S, et al. KEYNOTE-522: Phase 3 study of neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy, followed by adjuvant pembrolizumab versus placebo in early stage trile negative breast cancer. In: ESMO Virtual Plenary Virtual, 2021.